Baxter Awarded Pandemic Supply Contract From Department of Health
Baxter International Inc., (Deerfield, IL, www.baxter.com), has entered into an advanced supply agreement with the Department of Health that contains an option to purchase pandemic influenza vaccine in the event the World Health Organization (WHO) declares a pandemic.
Baxter International Inc., (Deerfield, IL, www.baxter.com), has entered into an advanced supply agreement with the Department of Health that contains an option to purchase pandemic influenza vaccine in the event the World Health Organization (WHO) declares a pandemic.
Baxter will manufacture its pandemic vaccine in a serum-free, vero cell-based system, at one of the largest cell culture vaccine facilities in the world. Vaccines produced using this process can be released within approximately 12 weeks, significantly earlier than with traditional egg-based systems. All influenza strains with pandemic potential tested for growth in vero cells have produced replicable high yields, providing the company with the ability to respond to emerging variant pandemic virus strains.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
FDA Reopens Comment Period on HCP Immunogenicity Risk of Follow-on Recombinant Peptides
January 2nd 2025FDA is reopening the comment period for the Federal Register Notice, “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments”, until March 3, 2025.
